California Public Employees Retirement System cut its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 7.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 485,027 shares of the biopharmaceutical company’s stock after selling 41,542 shares during the quarter. California Public Employees Retirement System owned 0.22% of Alexion Pharmaceuticals worth $60,216,000 at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Point72 Asia Hong Kong Ltd increased its stake in shares of Alexion Pharmaceuticals by 3,156.7% in the 1st quarter. Point72 Asia Hong Kong Ltd now owns 977 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 947 shares in the last quarter. Advisory Services Network LLC increased its stake in shares of Alexion Pharmaceuticals by 145.3% in the 2nd quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 523 shares in the last quarter. Lucia Wealth Services LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter worth $191,000. Berson & Corrado Investment Advisors LLC purchased a new stake in shares of Alexion Pharmaceuticals in the 2nd quarter worth $205,000. Finally, Financial Gravity Wealth Inc. purchased a new stake in shares of Alexion Pharmaceuticals in the 1st quarter worth $211,000. 93.06% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ ALXN traded up $2.63 during trading on Friday, hitting $121.94. The stock had a trading volume of 1,776,401 shares, compared to its average volume of 1,766,533. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.72 and a quick ratio of 2.27. The company has a market cap of $30.98 billion, a P/E ratio of 23.63, a PEG ratio of 1.27 and a beta of 0.79. Alexion Pharmaceuticals, Inc. has a one year low of $102.10 and a one year high of $144.91.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Thursday, July 26th. The biopharmaceutical company reported $2.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.49 by $0.58. Alexion Pharmaceuticals had a negative net margin of 2.68% and a positive return on equity of 15.21%. The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $976.81 million. During the same quarter last year, the firm earned $1.56 earnings per share. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 6.45 EPS for the current year.
A number of equities research analysts have issued reports on ALXN shares. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 13th. Barclays increased their price target on Alexion Pharmaceuticals to $175.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. Stifel Nicolaus lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating and cut their price target for the stock from $154.00 to $130.00 in a research note on Tuesday, August 7th. JPMorgan Chase & Co. increased their price target on Alexion Pharmaceuticals from $184.00 to $188.00 and gave the stock an “overweight” rating in a research note on Friday, July 27th. Finally, ValuEngine lowered Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, August 8th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $160.74.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Featured Story: Buyback
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.